title: Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.
abstract: OBJECTIVE
  To report the 12-month follow-up results of subfoveal polypoidal choroidal vasculopathy (PCV) patients treated with indocyanine green angiography (ICGA)-guided photodynamic therapy (PDT).
  
  
  METHODS
  Interventional, noncomparative cases series.
  
  
  METHODS
  A retrospective analysis of the clinical and angiographic data related to 47 PCV eyes that were followed up for 12 months was carried out. The greatest linear dimension (GLD) for PDT was determined based on the ICGA findings. Optical coherence tomography (OCT) also was used to evaluate the therapeutic effects.
  
  
  RESULTS
  The mean logarithm of the minimum angle of resolution visual acuity (VA; 0.58 +/- 0.37) significantly improved to 0.53 +/- 0.38 at three months (P = .04) and to 0.46 +/- 0.40 at 12 months (P = .02). The average ICGA GLD (2682.3 +/- 1026.9 mm) was significantly (P = .0001) smaller than the presumed fluorescein angiography (FA) GLD (4043.6 +/- 1914.8 mm). In more than 80% of cases, complete resolution of retinal exudative changes was observed. Although polypoidal vascular lesions disappeared in 82.2% of eyes, the branched vascular networks showed little change. The initial VA and GLD had little correlation with the VA outcome.
  
  
  CONCLUSIONS
  ICGA-guided PDT reduces the size of laser exposure and is an effective treatment for PCV. Because PCV may appear as occult choroidal neovascularization (CNV) on FA, PCV should be diagnosed using ICGA before treatment because PCV may respond differently than CNV to appropriate treatment.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. otan@kuhp.kyoto-u.ac.jp
authors.forename: Atsushi
authors.initials: A
authors.lastname: Otani
authors.forename: Manabu
authors.initials: M
authors.lastname: Sasahara
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yodoi
authors.forename: Hiroko
authors.initials: H
authors.lastname: Aikawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamura
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002829:Choroid / Q000098:blood supply*; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy*; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods*; D006801:Humans; D007208:Indocyanine Green; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000175:diagnosis / Q000188:drug therapy*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green